Investing.com report covering Envoy Medical Inc. (Class A) (COCH) market action, institutional positioning, and fundamental catalysts.
Why COCH Stock surged +2.00% Today — RQD Quant Desk Flash
Envoy Medical Inc. (Class A) (COCH) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is COCH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Envoy Medical Inc. (Class A) (NASDAQ: COCH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $6.63 (+2.00% 1D, market cap $50.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, COCH ranks #687 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does COCH compare to MYO and APT in the Health Care sector?
▼
Within the Health Care sector (Industrial Specialties), COCH carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, MYO (Myomo Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $51.5M) and APT (Alpha Pro Tech Ltd.) posts a C grade (62/100 RQD, P/E 16.2x, ROIC 6.7%, cap $56.6M). Among the 5-stock peer group, APT leads on earnings multiple (16.2x) while APT leads on capital efficiency (6.7% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for COCH?
▼
Per COCH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001840877), Envoy Medical Inc. (Class A) generated $241.0K in revenue (+7.1% YoY), -$23.8M in net income, and -$18.4M in free cash flow against $8.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 51% of 52W Range • RSI-14 at 47.9 (NEUTRAL RANGE)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
⚔️ Adversarial Opposing Case: What Could Spark a COCH Turnaround Squeeze
While COCH currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.84) and Max Pain ($6.96) forces dealer call-delta covering toward $10.02.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why COCH Stock surged +2.00% Today — RQD Quant Desk Flash
Envoy Medical Inc. (Class A) (COCH) surged +2.00% to $6.63, trading at 51% of its 52-week range ($3.63 – $9.54). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 51% of its 52-week range ($3.63 – $9.54) with RSI-14 at 47.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $6.63 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 0% gross margin and $0 annual free cash flow.
TradingView report covering Envoy Medical Inc. (Class A) (COCH) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Envoy Medical Inc. (Class A) (COCH) market action, institutional positioning, and fundamental catalysts.
TMX Newsfile report covering Envoy Medical Inc. (Class A) (COCH) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Envoy Medical Inc. (Class A) (COCH) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Envoy Medical Inc. (Class A) (COCH) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Envoy Medical Inc. (Class A) (COCH) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Envoy Medical Inc. (Class A) (COCH) market action, institutional positioning, and fundamental catalysts.
Financial Results to Be Released Before Market OpenWhite Bear Lake, Minnesota--(Newsfile Corp. - October 28, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosth
Management Will Host a Conference Call at 4:30 P.M. ET on the Same DayWhite Bear Lake, Minnesota--(Newsfile Corp. - October 27, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing hea
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring COCH)
- ✓Walkthrough of COCH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
COCH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +7.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on COCH today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for COCH. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (COCH)
1. Head-to-Head Health Care Peer Comparison (COCH vs. MYO, APT, NTRB, CNXU)
Industry: Industrial Specialties (55 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Envoy Medical Inc. (Class A) (COCH) ranks #687 by composite RQD confidence (35/100, grade D-) and #752 by equity capitalization ($50.3M). Within this direct 5-issuer industry benchmark cohort, APT leads on earnings valuation at 16.2x trailing P/E, while APT leads on capital efficiency and profitability with 6.7% ROIC and 38.1% gross margin. APT currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with COCH at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| COCH
ACTIVE
Envoy Medical Inc. (Class A) | D- | 35/100 | — | -30.0% | -35.0% | +2.00% | $50.3M | Benchmark Subject |
| MYO Myomo Inc. | E | 33/100 | — | 65.7% | -35.0% | -4.61% | $51.5M | /myo-vs-coch → |
| APT Alpha Pro Tech Ltd. | C | 62/100 | 16.2x | 38.1% | 6.7% | -2.70% | $56.6M | /apt-vs-coch → |
| NTRB Nutriband Inc. | D- | 39/100 | — | 27.8% | -35.0% | -5.12% | $80.7M | /ntrb-vs-coch → |
| CNXU Conexeu Sciences Inc. | D- | 43/100 | — | — | — | -10.25% | $85.8M | /cnxu-vs-coch → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001840877In its most recent audited fiscal period (FY2025, filed 2025-12-31), Envoy Medical Inc. (Class A) (COCH) reported GAAP revenue of $241.0K (+7.1% vs. FY2024 revenue of $225.0K , and -23.7% cumulative change since FY2023) , GAAP net income of -$23.8M, operating cash flow of -$18.2M, and free cash flow of -$18.4M (+2.9% YoY). On the balance sheet, COCH closed FY2025 with $8.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $241.0K | -$23.8M | -$18.2M | -$18.4M | $8.6M | — |
| FY2024 (FY) | 2024-12-31 | $225.0K | -$20.8M | -$17.9M | -$18.9M | $11.5M | — |
| FY2023 (FY) | 2023-12-31 | $316.0K | -$29.9M | -$17.1M | -$17.1M | — | — |
3. COCH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs COCH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Envoy Medical Inc. (Class A) (NASDAQ: COCH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $6.63 (+2.00% 1D, market cap $50.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, COCH ranks #687 in composite RQD confidence.
How does COCH compare to MYO and APT in the Health Care sector?
Within the Health Care sector (Industrial Specialties), COCH carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, MYO (Myomo Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $51.5M) and APT (Alpha Pro Tech Ltd.) posts a C grade (62/100 RQD, P/E 16.2x, ROIC 6.7%, cap $56.6M). Among the 5-stock peer group, APT leads on earnings multiple (16.2x) while APT leads on capital efficiency (6.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for COCH?
Per COCH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001840877), Envoy Medical Inc. (Class A) generated $241.0K in revenue (+7.1% YoY), -$23.8M in net income, and -$18.4M in free cash flow against $8.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is COCH trading relative to its 50-day, 200-day, and 52-week technical levels?
COCH last traded at $6.63 (+2.00% on volume of 48,375 shares), positioning the stock -3.07% below its 50-day simple moving average ($6.84) and -3.49% below its 200-day simple moving average ($6.87). Across its 52-week range of $3.63 to $9.54, COCH sits at the 50.8% percentile with a 14-day RSI of 47.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.80 to $7.46).
COCH Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is COCH stock moving today?
Why COCH Stock surged +2.00% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
COCH — Envoy Medical Inc. (Class A): What the Facts Mean to a Prospective Investor
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, COCH carries an RQD Score of 35 out of 100 and a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are scored as follows:
- Fundamental Cash Engine: 7 / 20. The source cites ROIC of -35% and an FCF yield of 0%. For a prospective investor, this indicates the business is not currently generating a return on invested capital or free cash flow to offset its operating losses.
- Whale 13F Flow: 7 / 20. The pillar reflects institutional accumulation and options positioning. The underlying holder-level detail is not available in source data, so the weak score cannot be decomposed further.
- Insider Conviction: 5 / 20. This is the lowest pillar and reflects SEC Form 4 and Congressional PTR cluster flow. The individual transactions are not itemized in the source data.
- Macro Regime Fit: 8 / 20. Beta is 1.0, and the pillar also reflects sector sensitivity. A beta of 1.0 means the stock is modeled to move in line with the broad market, offering no defensive cushion.
- Forensic Balance Sheet: 8 / 20. Per the source, the Altman Z-Score is 2.5, the Piotroski F-Score is 2 out of 9, and Debt/Equity is 0.5. A low Piotroski score points to weak financial-health signals across multiple tests.
Taken together, the pillar scores point to a company with negative economics, weak forensic signals, and limited evidence of institutional or insider conviction. Upside drivers would need to come from a sustained change in operating results, which the historical financials do not yet show. The valuation tradeoff is that the market is pricing a small-cap, loss-making issuer, and the rating frames the risk as balance-sheet and flow vulnerability rather than a near-term earnings recovery. This analysis is educational and is not personalized financial advice.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.2M | $-22.3M | $-23.8M | N/A | $-18.4M | N/A | N/A |
| FY 2024 | $0.2M | $-19.3M | $-20.8M | N/A | $-18.9M | N/A | N/A |
| FY 2023 | $0.3M | $-18.4M | $-29.9M | N/A | $-17.1M | N/A | N/A |
Per the SEC financials, revenue has been minimal across the three reported years ($0.3M, then $0.2M in each of the two subsequent years), while operating losses and free-cash-flow burn have persisted. Per the market data, gross margin is -30%, operating margin is -60%, and net margin is -60%, with ROIC at -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2 out of 9, per the Roarable RQD rating. Cash and debt balances are not available in source data, so the balance-sheet posture can only be assessed through the Debt/Equity ratio of 0.5 cited in the forensic pillar.
Recent Catalysts & News Wire Analysis
Per the recent news and catalysts section, the most prominent items are:
- Initiation coverage: Lake Street initiated coverage at a buy rating on the company's cochlear device.
- Reverse stock split: The company announced a 1-for-10 reverse split effective October 26, which the reporting describes as intended to help meet Nasdaq's $1 minimum bid requirement. Share-price weakness was also noted in one headline.
- Scheduled call: The company will host a call at 4:30 p.m. ET on November 5 following its third-quarter results.
All six items are tagged as YELLOW light signals under the MARKET WIRE impact label. Risk watch items include the reverse split's implications for the share count and the need to satisfy the Nasdaq minimum bid requirement. The butterfly supply-chain graph reports no proprietary signals.
Open Questions
- What are the company's products, customers, and revenue model, given that the source does not describe the business beyond its sector classification?
- What are the reported cash and debt balances, which are listed as N/A across all periods?
- What drove the sharp swing in FY 2023 net income relative to operating income, and what is the source of the difference?
- What is the company's path to positive operating cash flow, and what funding is available to sustain the current burn rate?
- What would the post-reverse-split share count and per-share metrics look like, and how will they affect EPS and market-cap comparisons?
COCH Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Envoy Medical Inc. (Class A) (COCH) • Click "Debate This Headline" to argue it in the Roar Pit below
Investing.com report covering Envoy Medical Inc. (Class A) (COCH) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Envoy Medical Inc. (Class A) (COCH) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Envoy Medical Inc. (Class A) (COCH) market action, institutional positioning, and fundamental catalysts.
TMX Newsfile report covering Envoy Medical Inc. (Class A) (COCH) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Envoy Medical Inc. (Class A) (COCH) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Envoy Medical Inc. (Class A) (COCH) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Envoy Medical Inc. (Class A) (COCH) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Envoy Medical Inc. (Class A) (COCH) market action, institutional positioning, and fundamental catalysts.
COCH Bull vs. Bear Conversation Board — What's Your Call at $6.63?
🔥 Official Bull vs. Bear Debate: Is COCH (D- • RQD 35/100) a Buy at $6.50?
Welcome to the COCH (Envoy Medical Inc. (Class A)) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Industrial Specialties. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Pump the brakes on COCH — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on COCH, but look at what you are paying: current EV/EBITDA multiples with -30.0% gross margins. Unless Envoy Medical Inc. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
COCH cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on COCH, the market is fixating on short-term headline noise in Industrial Specialties and ignoring the balance sheet and cash flow trajectory. At $6.50 (52-wk range $3.63 - $9.54), any beat on forward guidance forces shorts and underweight funds to chase.